Rafik Terra, Stéphanie Thiant, Jean-Sébastien Claveau, Jean Roy, Imran Ahmad, Richard LeBlanc
{"title":"Prognostic value and kinetic patterns of measurable residual disease following tandem autologous/allogeneic transplant in newly diagnosed myeloma patients.","authors":"Rafik Terra, Stéphanie Thiant, Jean-Sébastien Claveau, Jean Roy, Imran Ahmad, Richard LeBlanc","doi":"10.1038/s41409-025-02626-x","DOIUrl":"https://doi.org/10.1038/s41409-025-02626-x","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elizabeth F Krakow, Nathan Lee, Isaac Jenkins, Olga Sala-Torra, Lan Beppu, Jerald P Radich, Bryce Fukuda, Brenda M Sandmaier, Cecilia Cs Yeung, Ivana Bozic
{"title":"A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing.","authors":"Elizabeth F Krakow, Nathan Lee, Isaac Jenkins, Olga Sala-Torra, Lan Beppu, Jerald P Radich, Bryce Fukuda, Brenda M Sandmaier, Cecilia Cs Yeung, Ivana Bozic","doi":"10.1038/s41409-025-02602-5","DOIUrl":"https://doi.org/10.1038/s41409-025-02602-5","url":null,"abstract":"<p><p>Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones. We developed an online software (CloneTracker) that uses 'incidentally-sequenced' single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Tested on 29 patients who underwent non-myeloablative transplantation for AML, CloneTracker successfully reconstructed the evolutionary dynamics of donor engraftment from bulk NGS and rendered intuitive visualizations of residual patient-derived hematopoiesis and relapsing malignant clones. The software does not require sequencing donor samples, as donor-derived clones are identifiable from post-HCT SNP data. This manuscript aims to introduce CloneTracker to the BMT community and make it available for those who would ascertain its clinical utility, e.g, in BMT trials leveraging molecular minimal residual disease (MRD) monitoring and targeted interventions to pre-empt relapse.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nina Worel, Jarl E Mooyaart, Jorinde D Hoogenboom, Michael Daskalakis, Jean-Jacques Tudesq, Ron Ram, Vladan Vucinic, Stefania Bramanti, Lucía López Corral, Emma Nicholson, Robert Zeiser, Friedrich Stölzel, Eugenio Galli, Simona Pagliuca, Eva Wagner-Drouet, Friso Calkoen, Christian Chabannon, Florent Malard, Annalisa Ruggeri, Jürgen Kuball
{"title":"CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party.","authors":"Nina Worel, Jarl E Mooyaart, Jorinde D Hoogenboom, Michael Daskalakis, Jean-Jacques Tudesq, Ron Ram, Vladan Vucinic, Stefania Bramanti, Lucía López Corral, Emma Nicholson, Robert Zeiser, Friedrich Stölzel, Eugenio Galli, Simona Pagliuca, Eva Wagner-Drouet, Friso Calkoen, Christian Chabannon, Florent Malard, Annalisa Ruggeri, Jürgen Kuball","doi":"10.1038/s41409-025-02623-0","DOIUrl":"https://doi.org/10.1038/s41409-025-02623-0","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carmine Liberatore, Mario D'Uva, Annalisa Natale, Francesco Guardalupi, Lucia Di Re, Francesca Fioritoni, Stefano Pulini, Raffaele Spadano, Doriana Vaddinelli, Stella Santarone, Mauro Di Ianni
{"title":"Cytomegalovirus infection after autologous transplantation in patients with multiple myeloma exposed to daratumumab.","authors":"Carmine Liberatore, Mario D'Uva, Annalisa Natale, Francesco Guardalupi, Lucia Di Re, Francesca Fioritoni, Stefano Pulini, Raffaele Spadano, Doriana Vaddinelli, Stella Santarone, Mauro Di Ianni","doi":"10.1038/s41409-025-02624-z","DOIUrl":"https://doi.org/10.1038/s41409-025-02624-z","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giorgia Battipaglia, Myriam Labopin, Aleksandr Kulagin, Jurgen Versluis, Goda Choi, Ellen Meijer, Montserrat Rovira, Gwendolyn van Gorkom, Mi Kwon, Yener Koc, Jan Vydra, Patrizia Chiusolo, Amit Patel, Simona Piemontese, Jaime Sanz, Annalisa Ruggeri, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
{"title":"Addition of mycophenolate mofetil to a calcineurin inhibitor and post-transplant cyclophosphamide results in lower incidence of extensive chronic graft-versus-host disease in HLA-matched allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in complete remission: a matched-pair analysis on behalf of the Acute Leukemia Working Party of the EBMT.","authors":"Giorgia Battipaglia, Myriam Labopin, Aleksandr Kulagin, Jurgen Versluis, Goda Choi, Ellen Meijer, Montserrat Rovira, Gwendolyn van Gorkom, Mi Kwon, Yener Koc, Jan Vydra, Patrizia Chiusolo, Amit Patel, Simona Piemontese, Jaime Sanz, Annalisa Ruggeri, Arnon Nagler, Fabio Ciceri, Mohamad Mohty","doi":"10.1038/s41409-025-02610-5","DOIUrl":"https://doi.org/10.1038/s41409-025-02610-5","url":null,"abstract":"<p><p>Whether one or two agents added to post-transplant cyclophosphamide (PTCy) are needed in HLA-matched allogeneic hematopoietic stem cell transplantation (allo-HSCT) with peripheral blood stem cells (PBSC) is debated. We retrospectively compared PTCy in association with a calcineurin inhibitor (PTCy+CNI) or with a CNI plus mycophenolate mofetil (PTCy+CNI+MMF) in adult patients transplanted for acute myeloid leukemia in first complete remission and receiving PBSC in the period from 2010 to 2020. Propensity score matching was performed using exact matching for donor type (related or unrelated) and the nearest neighbor for other variables (i.e. age, adverse cytogenetics, Karnofsky performance status, patient and donor cytomegalovirus serology, conditioning intensity). Each group comprised 146 patients, with 63% in total undergoing matched unrelated-allo-HSCT. Median follow up was longer for PTCy+CNI (36 [IQR 31-39] months versus 25 [IQR 19-30] months for PTCy+CNI+MMF, p < 0.01). At 2 years, PTCy+CNI was associated with a higher incidence of extensive chronic GVHD (16% [95% CI 10-22] versus 6% [95% CI 3-12] for PTCy+CNI+MMF, p < 0.03) while no differences were observed for all the other transplant outcomes. Addition of MMF to PTCy and CNI may help to prevent extensive chronic GVHD in HLA-matched allo-HSCT with PBSC.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paula Y Arnold, Subodh Selukar, Guangjin Luo, Ying Li, Rebecca Epperly, Stephen Gottschalk, Renee M Madden, Amr Qudeimat, Akshay Sharma, Ali Y Suliman, Aimee C Talleur, Brandon M Triplett, Swati Naik
{"title":"HLA loss-mediated immune escape of acute leukemias in pediatric patients post haploidentical transplantation.","authors":"Paula Y Arnold, Subodh Selukar, Guangjin Luo, Ying Li, Rebecca Epperly, Stephen Gottschalk, Renee M Madden, Amr Qudeimat, Akshay Sharma, Ali Y Suliman, Aimee C Talleur, Brandon M Triplett, Swati Naik","doi":"10.1038/s41409-025-02622-1","DOIUrl":"https://doi.org/10.1038/s41409-025-02622-1","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Danniel Zamora, Hu Xie, Elizabeth Wong, Clarissa Santiano, Andrea Vivas-Jimenez, Alicja Sadowska-Klasa, Eleftheria Kampouri, Terry Stevens-Ayers, Masumi Ueda Oshima, Wendy M Leisenring, Joshua A Hill, Michael Boeckh
{"title":"ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients.","authors":"Danniel Zamora, Hu Xie, Elizabeth Wong, Clarissa Santiano, Andrea Vivas-Jimenez, Alicja Sadowska-Klasa, Eleftheria Kampouri, Terry Stevens-Ayers, Masumi Ueda Oshima, Wendy M Leisenring, Joshua A Hill, Michael Boeckh","doi":"10.1038/s41409-025-02611-4","DOIUrl":"https://doi.org/10.1038/s41409-025-02611-4","url":null,"abstract":"<p><p>We examined cytomegalovirus-specific cell-mediated immunity (CMV-CMI) to pp65 and IE-1 at 100 days after hematopoietic cell transplantation (HCT) following discontinuation of letermovir prophylaxis using ELISPOT (T-SPOT®.CMV, Oxford-Immunotec, Abingdon, UK). We compared ELISPOT results to a laboratory-developed intracellular cytokine staining (ICS) assay and characterized thresholds for the prediction of late clinically significant (cs)CMV infection using receiver operating characteristic analysis. We identified factors associated with high (i.e., at or above threshold) CMV-CMI to both antigens. ELISPOT correlated well with polyfunctional CMV-specific T-cell immunity by ICS. We defined thresholds of 67 and 4 spots per 250,000 cells for pp65 and IE-1, respectively, for predicting late csCMV infection. PBSC graft source, CMV seropositive donor, and/or CMV reactivation in the first 100 days post-HCT were associated with high CMV-CMI to pp65 and/or IE-1. Patients with high CMV-CMI to both antigens at day 100 had a lower incidence of late csCMV infection, however, late changes in immunosuppression affected risk prediction. Clinical risk factors (e.g., early CMV infection, acute graft-versus-host disease) predicted late csCMV and improved the predictive value of CMV-CMI testing. Thus, standardized CMV-CMI, after HCT, combined with clinical factors can be used to accurately stratify the risk of late csCMV infection after letermovir prophylaxis.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aqeeb Ur Rehman, Fathima Shehnaz Ayoobkhan, Moazzam Shahzad, Muhammad Kashif Amin, Sara Shatnawi, Sohaib Irfan, Sibgha Gull Chaudhary, Faiz Anwer, Joseph P McGuirk, Mohamad Mohty, Nausheen Ahmed, Al-Ola Abdallah, Muhammad Umair Mushtaq
{"title":"Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines.","authors":"Aqeeb Ur Rehman, Fathima Shehnaz Ayoobkhan, Moazzam Shahzad, Muhammad Kashif Amin, Sara Shatnawi, Sohaib Irfan, Sibgha Gull Chaudhary, Faiz Anwer, Joseph P McGuirk, Mohamad Mohty, Nausheen Ahmed, Al-Ola Abdallah, Muhammad Umair Mushtaq","doi":"10.1038/s41409-025-02604-3","DOIUrl":"https://doi.org/10.1038/s41409-025-02604-3","url":null,"abstract":"<p><p>Measurable residual disease (MRD) testing is emerging as a crucial prognostic and treatment-guiding tool in multiple myeloma (MM). Despite its potential, routine clinical adoption remains inconsistent. This study aimed to explore oncologists' perspectives on MRD testing and identify barriers and facilitators to its clinical integration. A cross-sectional, modified Delphi survey was conducted among hematologists and oncologists globally, and 115 responses were received. Our findings reveal significant variability in MRD testing, influenced primarily by specialty rather than geographic location, years of experience, or practice setting (academic vs community settings). Plasma cell-focused physicians were more likely to conduct routine MRD testing. Flow cytometry was the preferred testing methodology globally, with significant variations in acceptable negativity thresholds. The primary purpose of MRD testing was to guide treatment decisions; however, U.S. physicians employed it primarily to discuss results with patients. Key barriers to assessment included testing unavailability, lack of standardized guidelines, and, in non-U.S. settings, financial constraints. These findings highlight the need for consensus-driven guidelines to standardize MRD implementation, improve accessibility, and educate clinicians on its clinical utility. Addressing these gaps will be essential to leveraging MRD as a routine decision-making tool, ultimately optimizing patient outcomes in MM.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emily C Merkel, Christa L Meyer, Rafeek A Yusuf, Caroline F Morrison, Debra Lynch Kelly, Deena R Levine, Thomas W LeBlanc, Christina K Ullrich, Areej El-Jawahri
{"title":"What do pediatric transplant physicians think about palliative care? Results from a national survey study.","authors":"Emily C Merkel, Christa L Meyer, Rafeek A Yusuf, Caroline F Morrison, Debra Lynch Kelly, Deena R Levine, Thomas W LeBlanc, Christina K Ullrich, Areej El-Jawahri","doi":"10.1038/s41409-025-02597-z","DOIUrl":"https://doi.org/10.1038/s41409-025-02597-z","url":null,"abstract":"<p><p>The benefits of palliative care (PC) for hematopoietic cell transplant (HCT) patients are well established, however, uptake in pediatric HCT remains limited. To understand pediatric transplant physicians' attitudes towards PC, we conducted a cross-sectional study with a 28-question survey. A composite score and regression model identified factors associated with positive attitudes towards subspecialty PC. Ninety-eight participants reported caring for pediatric patients. Most (81%) trust PC clinicians to care for their patients, yet 33% feel PC clinicians lack enough HCT knowledge to counsel patients. Nearly half (46%) see the name \"PC\" as a barrier to referral. Multivariable analysis showed that spiritual practice (β = 1.53, p = 0.029), <10 years of clinical practice (β = 2.23, p = 0.007), and perceived PC quality (β = 0.73, p < 0.001) were associated with a more positive attitude towards PC. More training in PC (β = -2.70, p = 0.003) and a higher sense of ownership over PC issues (β = -0.51, p = 0.001) were associated with a more negative attitude towards subspecialty PC. These findings highlight barriers to pediatric HCT and PC collaboration, including concerns about PC team knowledge of HCT and patient perceptions. While most pediatric transplant physicians trust PC to enhance patient care, interventions are needed to improve collaboration.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
